An exoskeleton let a paralyzed man walk, then its maker refused repairs
A $100,000 medical exoskeleton that helped a paralyzed man walk became unusable when a small battery connector failed and the manufacturer initially refused to repair it, citing FDA limits on the device’s approved five‑year lifespan. Commenters debate whether this is primarily a right‑to‑repair problem, a regulatory failure, or a business decision, and how far companies should be required to provide parts, documentation, or long‑term support for niche but life‑changing medical devices. Proposals range from mandating standardized, documented components and post‑EOL parts access to tying regulatory approval, insurance coverage, or even source‑code escrow to guarantees that patients won’t lose essential functionality when a vendor stops servicing older models.
Right to Repair & Access to Parts
- Many see the case as a textbook argument for right-to-repair: users should have access to parts, documentation, and the ability to self-repair or use third parties.
- Others argue that in this case the user technically had the “right” to repair; the bottleneck was getting a discontinued, niche part manufactured.
- Debate over whether right-to-repair is a “negative right” (no blocking independent repair) or should become a “positive right” (obligation to provide parts/support for some period).
Proprietary vs. Standard Components
- Strong criticism of using proprietary or non-standard connectors when generic parts would suffice and stay sourceable long term.
- Counterpoint: proprietary components are ubiquitous (e.g., smartphones) and not inherently a right‑to‑repair violation unless combined with legal/technical barriers (DRM, licensing, pairing checks).
- Some argue that publishing specs/BOMs at end-of-life would let repair shops “bodge together” safe replacements, even for low-volume devices.
Regulation and FDA Constraints
- Disagreement over whether FDA rules truly barred the manufacturer from servicing the older device or if “regulations” were used as a convenient excuse.
- References to device “intended working life” (5 years) and how changes to control mechanisms may count as remanufacturing requiring new clearance.
- Some argue regulators should require backup/manual controls and separate non-medical peripherals (like remotes) from life‑span limits.
- Unclear from the thread exactly which FDA rule applied and whether the company could have lawfully serviced the device.
Economics, Niche Devices, and Support Lifetimes
- Concerns that mandating decades of parts support for ultra‑niche, $100k exoskeletons could kill innovation or be economically infeasible.
- Others note that long-term support is routine in sectors like cars and aircraft, and medical devices with life‑altering impact should have similar expectations.
- Suggestions that insurers/governments could require or fund long-term parts availability, or that such devices might better be leased with ongoing maintenance.
Healthcare Systems & Access
- U.S. Medicare coverage is partial and excludes some injury types; commenters see this as emblematic of U.S. healthcare friction.
- Some claim exoskeletons and advanced care are more straightforwardly covered in certain socialized systems; others say “fights with administration” exist there too.
Journalism & Missing Context
- Multiple commenters criticize the article for not deeply examining the FDA/regulatory angle, focusing instead on corporate blame.
- Some attribute this to underfunded, deadline‑driven journalism that can’t support detailed technical investigation.
Broader Policy Proposals
- Ideas floated include: mandatory post‑EOL open-sourcing of schematics/firmware, source‑code escrow tied to regulatory approval, or laws prioritizing consumers in bankruptcy so essential IP can be opened.
- Others warn these measures might clash with IP rights, creditor interests, and existing business/legal structures.